Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oligometastatic Prostate Adenocarcinoma
Conditions
Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
Trial Timeline
Dec 12, 2025 → Oct 31, 2031
NCT ID
NCT07150715About Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan
Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan is a phase 2 stage product being developed by Novartis for Oligometastatic Prostate Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07150715. Target conditions include Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Oligometastatic Prostate Adenocarcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07150715 | Phase 2 | Recruiting |
Competing Products
5 competing products in Oligometastatic Prostate Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium Lu-177 PNT2002 | Eli Lilly | Phase 2 | 39 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 3 | 47 |
| AAA617 | Novartis | Phase 3 | 47 |
| Quemliclustat + Etrumadenant + Zimberelimab | Arcus Biosciences | Phase 2 | 36 |